REHOVOT, Israel and BRIDGEWATER, New Jersey, June 15, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dov Tamarkin, PhD, Chief Executive Officer, will present a corporate overview and business update at the 2017 BIO International Convention, being held on June 19-22, 2017 at San Diego Convention Center, San Diego, CA.
Foamix Pharmaceuticals Presentation Details
Date: Thursday, June 22, 2017
Time: 01:30 pm Pacific Time
Location: Company Presentation Theater 3, San Diego Convention Center
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-to-present-at-the-2017-bio-international-convention-300474464.html
SOURCE Foamix Pharmaceuticals Ltd.